New drug shows promise for rare skin cancers

NCT ID NCT07132567

Recruiting now Disease control Sponsor: Kyowa Kirin Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is tracking how safe and effective the drug mogamulizumab (Poteligeo) is for adults with two rare types of skin lymphoma: mycosis fungoides and Sézary syndrome. Researchers will monitor 15 participants in routine care settings for side effects and how well the drug controls the disease. The goal is to see if the drug works in real-world use, not just in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mogamulizumab (Poteligeo)
What this could lead to: If successful, this could confirm that mogamulizumab works well and is safe for treating these rare skin lymphomas in everyday medical practice.
What could go wrong: This is a small, observational study with only 15 participants, so results may not apply to all patients. Side effects are possible, and the drug is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYCOSIS FUNGOIDES SEZARY SYNDROME

Contacts and locations

Locations

Chung-Ang University Hospital
TERMINATED

Seoul, South Korea
Ewha Womans University Mokdong Hospital
RECRUITING

Seoul, South Korea
Kosin University Gospel Hospital
RECRUITING

Busan, Busan Metropolitan City, 49267, South Korea
Samsung Medical Center
RECRUITING

Seoul, South Korea
Seoul National University Hospital
RECRUITING

Seoul, South Korea
Seoul National University Hospital
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.